Get the Stockscreener App
1.58
3.29%
0.06
Lava Therapeutics Nv stock is traded at $1.58, with a volume of 8,993.
It is up +3.29% in the last 24 hours and down -8.75% over the past month.
LAVA Therapeutics NV is a biotechnology company. It is focused on transforming cancer treatment by developing a platform to selectively induce bispecific antibody utilizing the Gammabody platform for an undisclosed tumor associated antigen for the treatment of cancer.
See More
Previous Close:
$1.52
Open:
$1.5
24h Volume:
8,993
Relative Volume:
0.19
Market Cap:
$41.55M
Revenue:
$9.06M
Net Income/Loss:
$-50.39M
P/E Ratio:
-1.026
EPS:
-1.54
Net Cash Flow:
$5.89M
1W Performance:
-5.42%
1M Performance:
-8.75%
6M Performance:
-40.75%
1Y Performance:
+5.37%
1-Day Range:
$1.50
$1.57
1-Week Range:
$1.50
$1.6673
52-Week Range:
$1.35
$6.47
Lava Therapeutics Nv Stock (LVTX) Company Profile
Compare LVTX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
| LVTX | 1.57 | 41.55M | 9.06M | -50.39M | 5.89M | -1.54 |
| VRTX | 448.08 | 115.74B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 745.19 | 81.65B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 588.39 | 34.86B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 248.24 | 32.09B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 103.02 | 24.49B | 3.30B | -501.07M | 1.03B | 11.54 |
Lava Therapeutics Nv Stock (LVTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-25-22 | Initiated | H.C. Wainwright | Buy |
| Apr-19-21 | Initiated | JP Morgan | Overweight |
| Apr-19-21 | Initiated | Jefferies | Buy |
| Apr-19-21 | Initiated | SVB Leerink | Outperform |
Lava Therapeutics Nv Stock (LVTX) Latest News
Lava Therapeutics' SWOT analysis: oncology biotech's stock potential amid trials - Investing.com UK
Xinhua News | Portuguese scientists discover new approach to combat Alzheimer's disease - Xinhua
After the Lykos debacle, what’s next for psychedelic therapies? - Pharmaceutical Technology
Positive Pooled Data from Nuvation Bio’s TRUST-I and TRUST-II Studies Highlight Taletrectinib’s Best-in-Class Potential for Patients with Advanced ROS1-positive NSCLC, Supporting Planned New Drug Application Submission in the Fourth Quarter of 2024 - BioSpace
LAVA Therapeutics Announces Appointment of Amy Garabedian as General Counsel and Corporate Secretary - Yahoo Finance UK
LAVA Therapeutics to Participate in the H.C. Wainwright 26th Annual Global Investment Conference - Yahoo Finance UK
LAVA Therapeutics to Participate in the H.C. Wainwright 2nd Annual Immune Cell Engager Virtual Conference - Yahoo Finance UK
LVTXLAVA Therapeutics N.V. Ordinary Shares Latest Stock News & Market Updates - StockTitan
LAVA Therapeutics (NASDAQ:LVTX) Given Market Outperform Rating at JMP Securities - Defense World
LAVA Therapeutics (NASDAQ:LVTX) Issues Earnings Results - Defense World
LAVA Therapeutics Faces Financial Hurdles - TipRanks
LAVA Reports Second Quarter 2024 Financial Results and Business Update - GlobeNewswire
LAVA Therapeutics NV expected to post a loss of 36 cents a shareEarnings Preview - XM
LAVA Therapeutics (NASDAQ:LVTX) Stock Price Up 2.3% - Defense World
All You Need to Know About LAVA Therapeutics (LVTX) Rating Upgrade to Strong Buy - Yahoo Finance Australia
LAVA Therapeutics (NASDAQ:LVTX) Shares Down 0.7% - American Banking and Market News
LAVA Therapeutics (NASDAQ:LVTX) Trading Down 0.7% - Defense World
Investors in LAVA Therapeutics (NASDAQ:LVTX) from a year ago are still down 16%, even after 44% gain this past week - Yahoo Lifestyle Australia
LAVA Therapeutics (NASDAQ:LVTX) Receives Buy Rating from HC Wainwright - Defense World
Cathie Wood's ARK ETF focuses on PagerDuty, 10X Genomics stock By Investing.com - Investing.com
Lava Therapeutics shares hold target with Buy rating By Investing.com - Investing.com India
Macquarie starts Ensign Group stock coverage with outperform rating By Investing.com - Investing.com India
Barclays sets Charles River Labs stock target with Equalweight rating By Investing.com - Investing.com India
Citi reaffirms sell on Dr. Reddy's shares amid acquisition deal By Investing.com - Investing.com
Jefferies sets buy rating on Syndax stock By Investing.com - Investing.com UK
UBS starts Hydro One stock coverage with neutral rating By Investing.com - Investing.com UK
Lava Therapeutics shares hold target with Buy rating - Investing.com India
JPMorgan starts PagerDuty stock with neutral rating amid 'competitive landscape' By Investing.com - Investing.com Australia
Cava group director Bosserman sells over $2.7 million in company stock By Investing.com - Investing.com Canada
Goldman Sachs sets target on Paramount shares, initiates with sell By Investing.com - Investing.com
Transocean adjusts share capital and treasury shares By Investing.com - Investing.com
LAVA Therapeutics Shareholders Approve Key ResolutionsTipRanks.com - TipRanks
Metric Analysis: LAVA Therapeutics NV (LVTX)'s Key Ratios in the Limelight – DWinneX - The Dwinnex
Kayne Anderson BDC stock gets Market Perform from KBW, notes stable industry focus By Investing.com - Investing.com
Biopharma Layoff Tracker 2024: Barinthus, Agilent, BMS and More Cut Staff - BioSpace
Kinsale Capital's president and COO sells shares worth over $579,000 By Investing.com - Investing.com South Africa
LAVA Announces Annual Meeting of Shareholders - GlobeNewswire
BioCardia secures patent for cardiac delivery catheter By Investing.com - Investing.com India
Karyopharm CEO sells shares worth $3,556 By Investing.com - Investing.com
Lava Therapeutics Nv Stock (LVTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.42%
0.16%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):